Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 804 KB, PDF-dokument
Pharmaceutical blockade of immune checkpoint inhibitors has become a cornerstone in the treatment of several malignancies. Many patients experience immune-related adverse events [Citation1]. However, treatment-related development or reactivation of infectious disease is rarely reported. Here, we present a patient with advanced non-small cell lung cancer (NSCLC), who developed tuberculosis (TB) following treatment with nivolumab, an anti-PD-1 monoclonal antibody.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Acta Oncologica |
Vol/bind | 57 |
Udgave nummer | 8 |
Sider (fra-til) | 1127-1128 |
Antal sider | 2 |
ISSN | 0284-186X |
DOI | |
Status | Udgivet - 3 aug. 2018 |
ID: 357371239